News | September 27, 2024
Torrent Pharmaceuticals refutes claims of Shelcal 500 allegedly failing CDSCO quality test
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
The sample seized by CDSCO is not manufactured by Torrent and is in fact non-genuine and spurious
This approval reflects company’s unwavering commitment that the quality assurance
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
The recent inspection covered both cGMP and PAI processes
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
The inspection was concluded with two 483 observations
Subscribe To Our Newsletter & Stay Updated
